PHA-793887 316 Combined treatment with Halofuginone and

Combined treatment with Halofuginone and Cisplatin significantly suppresses the tumor volume compared to treatment with Halofuginone or cisplatin alone

and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases

α1-adrenergic (pKi = 7

which binds to the HM/PIF binding pocket rather than the ATP-binding site

Fresquet V

PHA-793887 316 Combined treatment with Halofuginone andPHA 793887 is an inhibitor of multiple cyclin dependent kinases (CDK) with activity against CDK2, CDK1 and CDK4. PHA 793887 was cytotoxic for leukemic cell lines in vitro, with IC(50) ranging from 0. 3 to 7 microM. In colony assays PHA 793887 showed very high activity against leukemia cell lines, with an IC(50) <0. 1 microM indicating that it has efficient and prolonged antiproliferative activity. PHA 793887 induced cell cycle arrest, inhibited Rb and